

See Paper #10

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>RECEIVED</b>	
Date Submitted: February 28, 2002		MAR 01 2002	
(use as many sheets as necessary)			
Sheet	1	of	3
		Attorney Docket Number 078883-0134	

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

#### **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	6/24/04
-----------------------	---	--------------------	---------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Complete if Known

RECEIVED

MAR 01 2002

1636 TECH CENTER 1600/2900

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

 Date Submitted: February 28, 2002  
*(use as many sheets as necessary)*

Sheet 2 of 3

Application Number	09/937,295
Filing Date	11/29/2001
First Named Inventor	Mark UDEN
Group Art Unit	1646
Examiner Name	Unassigned

Attorney Docket Number 078883-0134

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
QN	A15	PURCELL, DAMIAN et al., "Alternative Splicing of Human Immunodeficiency Virus Type 1 mRNA Modulates Viral Protein Expression, Replication, and Infectivity, 1993, <u>J. of Virology</u> 67:6365-6378	Y
	A16	BRODY, BRIAN et al., "Postassembly Cleavage of a Retroviral Glycoprotein Cytoplasmic Domain Removes a Necessary Incorporation Signal and Activates Fusion Activity", 1994, <u>J. of Virology</u> 68:4620-4627	Y
	A17	REIN, ALAN et al., "Function of the Cytoplasmic Domain of a Retroviral Transmembrane Protein: p15E-p2E Cleavage Activates the Membrane Fusion Capability of the Murine Leukemia Virus Env Protein, 1994, <u>J. of Virology</u> , 68:1773-1781	Y
	A18	MAULIK, SUNIL et al., "Molecular Biotechnology: Therapeutic Applications and Strategies", 1997, Wiley-Liss, Inc., pp.45	Y
	A19	DOUGHERTY, JOSEPH P. et al., "A promoterless retroviral vector indicates that there are sequences in U3 required for 3' RNA processing", 1987, <u>Proc. Natl. Acad. Sci.</u> , 84:1197-1201	Y
	A20	HAWLEY, ROBERT et al., "Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells", 1987, <u>Proc. Natl. Acad. Sci.</u> , 84:2406-2410	Y
	A21	Yee, JIING-KUAN et al., "A general method for the generation of high-titer, pantrropic retroviral vectors: Highly efficient infection of primary hepatocytes", 1987, <u>Proc. Natl. Acad. Sci.</u> , 81:9564-9568	Y
	A22	JOLLY, DOUGLAS J. et al., "Elements in the terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene", 1983, <u>Nucleic Acids Research</u> , 11:1855-1872	Y
	A23	EMERMAN, MICHAEL et al., "Genes with Promoters in Retrovirus Vectors Can Be Independently Suppressed by an Epigenetic Mechanism", 1984, <u>Cell</u> , 39:449-467	Y
	A24	HERMAN, STEVEN A. et al., "Efficient Packaging of Readthrough RNA in ALV: Implications for Oncogene Transduction", 1987, <u>Science</u> , 236:845-848	Y
	A25	MILLER, DUSTY A. et al., "A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): Gene transfer into cells obtained from humans deficient in HPRT", 1983, <u>Proc. Natl. Acad. Sci.</u> , 80:4709-4713	Y
	A26	MILLER, DUSTY A. et al., "Improved Retroviral Vectors for Gene Transfer and Expression", 1989, <u>BioTechniques</u> , 7:980-990	Y
	A27	KRALL, WJ et al., "Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells", 1996, <u>Gene Therapy</u> , 3:37-48	Y
QN	A28	OVERELL, ROBERT W. et al., "Stably Transmitted Triple-Promoter Retroviral Vectors and Their Use in Transformation of Primary Mammalian Cells", <u>Molecular and Cellular Biology</u> , 8:1803-1808	Y

Examiner Signature

*2. D. Moyer*

Date Considered

6/24/04


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Complete if Known

RECEIVED

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: February 28, 2002

(use as many sheets as necessary)

Sheet

3

of

3

Application Number	09/937,295	MAR 01 2002 1646 1636 TECH CENTER 1600/2900
Filing Date	11/29/2001	
First Named Inventor	Mark UDEN	
Group Art Unit	1646	
Examiner Name	Unassigned	

Attorney Docket Number

078883-0134

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
QW	A29	CEPKO, CONSTANCE L. et al., "Construction and Applications of a Highly Transmissible Murine Retrovirus Shuttle Vector", 1984, <u>Cell</u> , 37:1053-1062	Y
	A30	KORMAN, ALAN J. et al., "Expression of human class II major histocompatibility complex antigens using retrovirus vectors", 1987, <u>Proc. Natl. Acad. Sci.</u> , 84:2150-2154	Y
	A31	DRANOFF, GLENN et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity", 1993, <u>Proc. Natl. Acad. Sci.</u> , 90:3979-3986	Y
	A32	LEE, FRANK et al., "Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids", 1981, <u>Nature</u> , 294:228-232	Y
	A33	LEWIS, JOHN A. et al., "Structure and Expression of the Chinese Hampster Thymidine Kinase Gene", 1986, <u>Molecular and Cellular Biology</u> , 6:1998-2010	Y
	A34	CHAPMAN, BARBARA S. et al., "Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells", 1991, <u>Nucleic Acids Research</u> , 19:3979-3986	Y
	A35	BENDER, MICHAEL A. et al., "Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region", 1987, <u>J. of Virology</u> , 61:1639-1646	Y
	A36	NALDINI, LUIGI et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", 1996, <u>Science</u> , 272:263-267	Y
	A37	KIM, MARRY V. et al., "Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1", 1998, <u>J. of Virology</u> , 72:811-816	Y
	A38	POESCHLLA, ERIC M. et al., "Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors", 1998, <u>Nature Medical</u> , 4:354-357	Y
	A39	FENG, MEIZHEN et al., "Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector", 1997, <u>Nature Biotechnology</u> , 15:866	Y
	A40	AEBI, M. et al., "Precision and orderliness in splicing", <u>Trends in Genetics</u> , 3:102-107	Y
QW	A41	BOTHWELL, ALFRED L. et al., "Heavy Chain Variable Region Contribution to the NPb Family of Antibodies: Somatic Mutation Evident in a y2a Variable Region", 1981, <u>Cell</u> , 24:625-637	Y

Examiner Signature		Date Considered	6/24/104
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Based on Form PTO-1449 (3/90)			ATTY. DOCKET NO. <b>674523-2020</b>	SERIAL NO. <b>09/937,295</b>			
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)			APPLICANT <b>Uden, et al.</b>				
			FILING DATE <b>November 29, 2001</b>	GROUP <b>1636</b>			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>QW</b>	AA	6,544,771	04/08/03	Riviere et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
							NO
	AL						
	AM						
	AN						
	AO						
	AP						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
EXAMINER <i>Lynne</i>				DATE CONSIDERED <b>6/24/04</b>			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							